BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31229165)

  • 1. Targeting Biology in Non-Hodgkin Lymphoma.
    Narkhede M; Yazdy MS; Cheson BD
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):727-738. PubMed ID: 31229165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncellular Immune Therapies for Non-Hodgkin Lymphoma.
    Herrera AF
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):707-725. PubMed ID: 31229164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting indolent non-Hodgkin lymphoma.
    Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
    Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current status and future impact of targeted therapies in non-Hodgkin lymphoma.
    Ujjani C; Cheson BD
    Expert Rev Hematol; 2013 Apr; 6(2):191-202; quiz 203. PubMed ID: 23547867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
    Phillips T; Brunvand M; Chen AI; Essell J; Chiappella A; Diefenbach C; Cheng J; Ramies D; Hirata J; Morschhauser F; Flinn IW
    Am J Hematol; 2022 Jan; 97(1):E24-E27. PubMed ID: 34731510
    [No Abstract]   [Full Text] [Related]  

  • 6. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
    Mehta A; Forero-Torres A
    Curr Oncol Rep; 2015 Sep; 17(9):41. PubMed ID: 26194424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
    Joshi M; Ansell SM
    J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative strategies in lymphoma therapy.
    Jäger U
    Wien Klin Wochenschr; 2003 Aug; 115(13-14):462-70. PubMed ID: 13677264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Malignant lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma)].
    Kinoshita T
    Rinsho Ketsueki; 2012 Feb; 53(2):145-54. PubMed ID: 22450573
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical investigations in aggressive non-Hodgkin lymphoma.
    Jonathan F
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):7-8. PubMed ID: 18998259
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapies in non-Hodgkin lymphoma.
    Novelli S; Sierra J; Briones J
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):349-59. PubMed ID: 25582186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD20-negative relapse after (131)I-anti-CD20 therapy.
    Venugopal P; Leslie WT; O'Brien T; Gregory SA
    J Clin Oncol; 1999 Nov; 17(11):3692-3. PubMed ID: 10550173
    [No Abstract]   [Full Text] [Related]  

  • 15. Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
    Cheson BD
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):4-6. PubMed ID: 18998258
    [No Abstract]   [Full Text] [Related]  

  • 16. [Is lymphoma curable with antibody therapy?].
    Leppä S; Nyman H; Karjalainen-Lindsberg ML
    Duodecim; 2009; 125(3):267-73. PubMed ID: 19341039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging treatment options for B-cell lymphomas.
    Zelenetz AD
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):666-9. PubMed ID: 25995425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal Antibodies.
    Geskin LJ
    Dermatol Clin; 2015 Oct; 33(4):777-86. PubMed ID: 26433849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in targeted therapy for malignant lymphoma.
    Wang L; Qin W; Huo YJ; Li X; Shi Q; Rasko JEJ; Janin A; Zhao WL
    Signal Transduct Target Ther; 2020 Mar; 5(1):15. PubMed ID: 32296035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Expert Rev Hematol; 2017 Sep; 10(9):775-782. PubMed ID: 28665214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.